Latest Conference Articles

December 10th 2021, 7:22pm

San Antonio Breast Cancer Symposium

Patricia A. Ganz, MD, discusses the quality of life results from the phase 3 OlympiA trial in BRCA-mutated breast cancer.

December 10th 2021, 7:20pm

San Antonio Breast Cancer Symposium

Megan Kruse, MD, discusses the results of a study comparing clinical features and outcomes of pleomorphic vs non-pleomorphic invasive lobular carcinoma.

December 10th 2021, 6:22pm

San Antonio Breast Cancer Symposium

Fulvestrant plus the CDK7 inhibitor samuraciclib demonstrated encouraging efficacy in patients with hormone receptor-positive breast cancer who were heavily pretreated with CDK4/6 inhibitors.

December 9th 2021, 10:17pm

ASH Annual Meeting and Exposition

Second-line lisocabtagene maraleucel demonstrated a favorable improvement in most patient-reported outcome domains compared with standard of care in patients with relapsed or refractory large B-cell lymphoma, and health-related quality of life was found to either be improved or maintained following treatment with the CAR T-cell therapy.

December 9th 2021, 9:45pm

San Antonio Breast Cancer Symposium

Physicians treating patients with early-stage triple-negative breast cancer should employ circulating tumor DNA testing early and often, according to results from the phase 2 cTRAK TN trial.

December 9th 2021, 9:20pm

San Antonio Breast Cancer Symposium

Trastuzumab deruxtecan led to prolonged progression-free survival and higher responses vs trastuzumab emtansine as second-line therapy in patients with HER2-positive metastatic breast cancer across all patients subgroups, including those with and without baseline brain metastases.

December 9th 2021, 9:04pm

San Antonio Breast Cancer Symposium

Peter Schmid, MD, PhD, FRCP, discusses additional results from the phase 3 KEYNOTE-522 trial in early-stage triple-negative breast cancer.

December 9th 2021, 9:01pm

San Antonio Breast Cancer Symposium

Sara A. Hurvitz, MD, discusses the results of subgroup analyses from the phase 3 DESTINY-Breast03 trial in patients with HER2-positive metastatic breast cancer.

December 9th 2021, 8:38pm

San Antonio Breast Cancer Symposium

Pyrotinib plus capecitabine exhibited longer overall survival (OS), compared with lapatinib plus capecitabine, in patients with HER2-positive breast cancer

December 9th 2021, 5:55pm

ASH Annual Meeting and Exposition

Not only is the 2021 ASH Annual Meeting bursting with more than 5000 abstracts unveiling pivotal data across a range of hematologic malignancies and disorders, but the conference will be held as a hybrid format after going fully virtual in 2020.

December 9th 2021, 5:41pm

San Antonio Breast Cancer Symposium

Prior research has shown that the combination of trastuzumab deruxtecan plus pertuzumab may be superior to T-trastuzumab deruxtecan alone in patients with HER2-positive metastatic breast cancer and the combination is now under examination in the phase 3 DESTINY-Breast09 trial.

December 9th 2021, 5:31pm

San Antonio Breast Cancer Symposium

Adjuvant treatment with neratinib or ado-trastuzumab emtansine resulted in a greater reduction in the risk of disease recurrence compared with other therapies in an epidemiologic model of HER2-positive, early-stage breast cancer.

December 9th 2021, 2:41pm

San Antonio Breast Cancer Symposium

The addition of the bispecific antibody zanidatamab to single-agent chemotherapy was found to produce promising antitumor activity with acceptable tolerability in heavily pretreated patients with HER2-positive breast cancer.

December 8th 2021, 10:40pm

San Antonio Breast Cancer Symposium

Significant outcome differences were observed in premenopausal vs postmenopausal patients with hormone receptor–positive, HER2-negative breast cancer who had 1 to 3 positive lymph nodes and received adjuvant chemotherapy as well as endocrine therapy.

December 8th 2021, 10:39pm

San Antonio Breast Cancer Symposium

A non-chemotherapy–based targeted regimen comprised of tucatinib, palbociclib, and letrozole resulted in prolonged central nervous system progression-free survival in patients with hormone receptor–positive, HER2-positive breast cancer.

December 8th 2021, 10:05pm

San Antonio Breast Cancer Symposium

Aromatase inhibitors significantly reduced the risk of breast cancer recurrence in premenopausal women with estrogen receptor–positive breast cancer receiving ovarian suppression compared with tamoxifen.

December 8th 2021, 9:12pm

San Antonio Breast Cancer Symposium

Black patients with breast cancer were more likely to experience treatment modifications or discontinuations in the neoadjuvant setting compared with White patients.

December 8th 2021, 8:22pm

San Antonio Breast Cancer Symposium

Kevin Kalinsky, MD, MS, discusses updated results from the phase 3 RxPONDER trial in patients with hormone receptor-positive, HER2-negative breast cancer.

December 8th 2021, 7:12pm

San Antonio Breast Cancer Symposium

First-line treatment with ribociclib/letrozole improved overall survival over placebo in patients with postmenopausal, hormone receptor–positive, HER2-negative advanced breast cancer, irrespective of metastatic site, number of sites, or prior (neo)adjuvant chemotherapy and endocrine therapy.

December 8th 2021, 6:40pm

San Antonio Breast Cancer Symposium

Survey data collected from more than 1400 laboratories around the world have demonstrated poor agreement in the evaluation of patients with breast cancer who have a low HER2 immunohistochemistry score of 0 or 1+ using standard HER2 assays.